Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →What's hot!
View all perspectives
What's Hot
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented in London at the EULAR 2026 Congress.
Watch video →
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 17 hours ago
#EULAR2026 OP0340 WK84 data of single arm Phase 2 Daratumumab (CD38 plasma depleter) weekly for 8 doses with background IS in N=10 #SLE: rapid reduction of antidsDNA & efficacy. 6/10 relapsed from WK20; 5/10 had low IgG and needed IVIG. Promising but Not so durable @RheumNow https://t.co/UrTywqkQ4F
Aurelie Najm AurelieRheumo
6 days 17 hours ago
What does remission look like for people living with PsA?
Much more than the absence of swollen joints
Absence of pain
Skin management
Ability to resume daily activities
Sustained over time
A definition not always reflected in our disease activity scores
#POS0294 #EULAR2026 https://t.co/VCnMGAOVYm
Nelly ZIADE 🍀 Nellziade
6 days 17 hours ago
Interesting poster #POS0939 from @SteZhao #EULAR2026
Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals
11,611 HLA-B27+ UK biobank
Recall bias? Yes but self-reported exposure validated with primary care data
@RheumNow https://t.co/VmxI3BW6FE
Jiha Lee JihaRheum
6 days 17 hours ago
Can AI read 20yrs of #RA X-rays as well as experts? RADAR algorithm scored 7,560 joints from the ESPOIR cohort: accuracy 0.94, sensitivity 0.92, specificity 0.95. AI-assisted radiographic scoring at scale and at the point of care may be here. @RheumNow #EULAR2026 OP0344
Nelly ZIADE 🍀 Nellziade
6 days 17 hours ago
Have you ever thought of diclofenac as an environmental pollutant?
Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026
@rheumnow https://t.co/RJWB6DmiZh
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 17 hours ago
#EULAR2026 OP0338 More evidence for treatment-to-target in #SLE. Longitudinal renal function analysis of Asia Pacific cohort: achieving LLDAS at least 50% of the time (LLDAS50) is assoc. with reduced eGFR decline independent of age, baseline eGFR, & renal involvement @RheumNow https://t.co/KduU1qtkhF
sheila RHEUMarampa
6 days 17 hours ago
In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP.
At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+
POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr
Nelly ZIADE 🍀 Nellziade
6 days 17 hours ago
Understanding how Bispecific T cell engagers work: remarkable mode of action!
Let’s hope it works as well as in oncology!
#teclistamab in #SSc
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/waSCXKA79Y
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 17 hours ago
#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw
Nelly ZIADE 🍀 Nellziade
6 days 17 hours ago
#CAR_T cell therapy in #SSc
Promising results from the Breakfree-1 study
(Zola-cel) on safety and preliminary efficacy on pFVC in 26 patients
More data is needed
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/ZS1LnBLMu5
Nelly ZIADE 🍀 Nellziade
6 days 18 hours ago
Looking forward to CAR T cell therapy trials in #SSc
Phase 2 and 3 studies presented at
#HOT session by Pr Oliver Distler
#CAR_T
#EULAR2026 @RheumNow https://t.co/bmXZpF2wKg
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 18 hours ago
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H
Antoni Chan MD (Prof) synovialjoints
6 days 18 hours ago
Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy
Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8
Nelly ZIADE 🍀 Nellziade
6 days 18 hours ago
Many drugs in the pipeline for #Systemic_Sclerosis
In particular, stay tuned for:
🔺Nerandomilast (PDE4i) in ILD
🔺CAR T cells (obviously): big RCT trials planned
🔺Bispecific T cell engagers: Teclistamab
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/I7HQtfwuW0
Mrinalini Dey DrMiniDey
6 days 18 hours ago
#OP0350 UK Biobank analysis found widespread white matter microstructural abnormalities on diffusion MRI in RA, esp in fronto-subcortical & transcallosal pathways, despite no cortical volume/thickness differences on T1 MRI. #EULAR2026 @RheumNow
